Fairfax, Va.-based George Mason University is leading a phase 2 clinical trial of ARD-201, an oral medication designed to help patients maintain weight loss after stopping GLP-1 treatments such as Ozempic and Wegovy.
The university is one of six sites participating in the open-label trial of the experimental drug, developed by Aardvark Therapeutics, according to a Jan. 9 news release. The drug works by activating bitter taste receptors in the gut and brain to suppress appetite, without producing an actual bitter taste.
The study will enroll adults who lost weight using injectable GLP-1s and have since discontinued them. Researchers will track weight regain and compare outcomes to typical post-treatment patterns.
If results from the phase 2 study are promising, researchers said they could inform larger, randomized trials to evaluate the drug’s long-term effectiveness.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
